Skip to content

Kodiak Sciences Inc KOD Return on equity

Return on equity at other companies

Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
14.5%-1.4pp
HRO
HarrowHROW
-50%+17.5pp
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
-58.1%+7.9pp
Ocular Therapeutix logo
Ocular TherapeutixOCUL
-68.6%+17.0pp
Stoke Therapeutics, Inc. logo
Stoke Therapeutics, Inc.STOK
-45.6%-66.1pp
Vera Therapeutics logo
Vera TherapeuticsVERA
-71.3%+296pp

Other financials

Income statement

See full
Operating income-$59.8M-1.2%
Net income-$58.2M-1.2%
EPS (diluted)-$0.94+13.8%

Balance sheet

See full
Cash & equivalents$169.5M+22.1%
Total debt$56.0M-17.2%
Total equity$112.1M+3.0%
Total assets$306.0M+2.7%

Cash flow

See full
Operating cash flow-$40.0M-37.6%
CapEx$942.0K+249%
Free cash flow-$41.0M-39.5%

Valuation

See full
Market cap$2.32B+1,477%
Enterprise value$2.2B+2,798%

Returns & leverage

See full
Debt / equity0.5×-0.1×
Current ratio3.5×-1.1×

Where this comes from

Calculated from Kodiak Sciences Inc’s reported figures.

Based on trailing twelve months.

The official record: Kodiak Sciences Inc’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Kodiak Sciences Inc's return on equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Kodiak Sciences Inc's return on equity?
Kodiak Sciences Inc (KOD) reported return on equity of -208.8% in Q1 2026.
How has Kodiak Sciences Inc's return on equity changed year-over-year?
Kodiak Sciences Inc's return on equity decreased by 91.7% year-over-year, from -108.9% to -208.8%.
What is the long-term trend for Kodiak Sciences Inc's return on equity?
Over 5 years (2020 to 2025), Kodiak Sciences Inc's return on equity has grown at a 46.6% compound annual growth rate (CAGR), from -22.1% to -149.5%.
What does return on equity mean?
Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.